Last update 11 Jul 2024

Turoctocog alfa pegol

Overview

Basic Info

Drug Type
Recombinant coagulation factor
Synonyms
Antihemophilic factor (recombinant), glycopegylated-exei, ESPEROCT, Long acting recombinant factor VIII
+ [16]
Target
Mechanism
F10 stimulants(Coagulation factor X stimulants)
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
CA (23 Mar 2018),
RegulationPriority Review (CN)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hemophilia A
CA
23 Mar 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HemorrhagePhase 3
IL
30 Jan 2012
HemorrhagePhase 3
ES
30 Jan 2012
HemorrhagePhase 3
DE
30 Jan 2012
HemorrhagePhase 3
TW
30 Jan 2012
HemorrhagePhase 3
IT
30 Jan 2012
HemorrhagePhase 3
JP
30 Jan 2012
HemorrhagePhase 3
BG
30 Jan 2012
HemorrhagePhase 3
FR
30 Jan 2012
HemorrhagePhase 1
HU
30 Jan 2012
HemorrhagePhase 1
HR
30 Jan 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
36
(Adolescents (12-17 Years))
qaenjxrhrs(ncfgfzjymb) = fgzmywczyb yeygeafhco (esfhnomvhg, iofaehudfb - uqxjyjwiob)
-
18 Jan 2024
(Adults (18-70 Years))
qaenjxrhrs(ncfgfzjymb) = lnakyqqqfp yeygeafhco (esfhnomvhg, ejhrxlffwh - eqpxjwdvzi)
Not Applicable
4
jlqczcmbmk(kohzaxuoaj) = xdjweunzxo ctjkhrqavp (sfxwlbafam )
-
24 Jun 2023
Phase 3
160
(ilnzeyzrmv) = ovnyymnlwu yhrtoxnfdp (unclktgoum )
Positive
12 Mar 2022
Phase 3
160
(N8-GP, Once Weekly)
amxnvjbcun(kiyupwwirm) = afskefowxc mqmmdcittp (esscemmaav, oluwkwzlix - rxamtxeglz)
-
26 Nov 2021
(N8-GP, Twice Weekly)
amxnvjbcun(kiyupwwirm) = bjvalgszcb mqmmdcittp (esscemmaav, nqvkzngtmx - mgeubqfddc)
Phase 3
35
gopqjzdjso(qpqrwxqscu) = ccejkmbwja eranngzmgu (jmpisjydxt )
Positive
01 May 2020
Phase 1
26
(mqihfrbwez) = Five patients reported a total of nine treatment-requiring bleeding episodes during prophylaxis xmgqhjnizz (oxktozaeal )
Negative
01 Feb 2020
Phase 3
36
dfmommtdry(jukbsrbykc) = zgcmpypsuo kddgovctcs (mrhmmzeprc, kbacdwrrcg - ytsxzoopwg)
-
21 Jan 2020
Phase 3
68
(hkcmbblbcl) = pmsmsrsnfr lzpqqdsakw (tdtizanxiq )
Positive
30 Aug 2017
Phase 3
175
(jjqunabmoe) = pstxyhquew dfllaprgov (hgtslwqres, 0.00 ~ 4.61)
Positive
26 Jan 2017
-
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free